Abstract
A high yielding and remarkably stereoselective α-methylation reaction of the (2S,3aS,7aS) stereoisomer of octahydroindole-2-carboxylic acid, (S,S,S)-Oic, suitably protected is described. The severe steric hindrance imposed by the fused cyclohexane ring, which prevents the application of Seebach’s self-reproduction of chirality methodology, accounts for the formation of (S,S,S)-(αMe)Oic with high selectivity and retention of configuration.
Keywords: quaternary amino acid, bicyclic proline analogue, perhydroindole-2-carboxylic acid, α-alkylation
The incorporation of conformationally constrained α-amino acids into bioactive peptides is an effective strategy to circumvent the toughest issues in the development of peptide drugs: proteolytic degradation and poor bioavailability.1 Quaternary α-amino acids have proved particularly useful to produce modified peptides with drug-like properties.2 The introduction of an alkyl chain at the α-carbon of an amino acid elicits, when incorporated into a peptide, conformational constraints that cannot only enhance the biological activity, but also improve the resistance to proteolysis and ultimately increase the bioavailability. Additionally, quaternary α-amino acids are invaluable tools to elucidate the receptor-bound conformation of bioactive peptides and to gain insight on the three dimensional structure of protein receptors that play critical roles in physiological processes.
Quaternary proline analogues3 have received considerable attention as these residues limit the conformational freedom of peptides. The modulation of the cis-trans proline amide geometry can allow stable arrangements of turns, which are fundamental recognition elements for peptide function.
Octahydroindole-2-carboxylic acid (Oic, Fig. 1) is a proline surrogate with a fused bicyclic structure shown to be a very useful scaffold. Among the eight different stereoisomers, (2S,3aS,7aS)-Oic (Fig. 1) has application in the elaboration of medicinally relevant drugs already in the market.4 This particular isomer has also been used as a surrogate of proline in large peptide systems such as bradykinin, thereby making feasible the preparation of orally available antagonists to the B2 receptor of this hormone, with attractive anti-cancer properties and enhanced resistance to degrading enzymes.5 It has also served as a β-turn inducer in the design of alternative non-peptidic bradykinin B2 antagonists.6 Additionally, some applications of (S,S,S)-Oic7 derivatives have been reported in the field of organocatalysis.8 Given the interest of this Oic stereoisomer, considerable efforts have been directed towards its preparation. The strategies reported in the literature include stereoselective processes,9 chemical resolutions of diastereomeric salts,10 and chromatographic11 and enzymatic12 resolutions.
Figure 1.
Structure of (2S,3aS,7aS)-octahydroindole-2-carboxylic acid.
As quaternary proline surrogates, (αMe)Oic derivatives are highly valuable systems for peptide engineering purposes due to their conformationally well-defined structures. Moreover, a number of quaternary Oic derivatives have been reported to be the core structure of investigational compounds with potential applications for treating osteoarthritis.13 However, the preparation of Cα-tetrasubstituted Oic analogues remains almost unexplored.13,14 The lack of effective methodologies for ready accessibility to their enantiomerically pure forms constitutes the main hurdle for their exploitation.
Recently, we have described a very convenient and concise route leading to enantiopure (R,S,S)-(αMe)Oic14 (Scheme 1) through a completely diastereoselective α-methylation reaction of the trichloromethyloxazolidinone15 derived from enantiopure (R,S,S)-Oic [(R,S,S)-1, Scheme 1]. The preparation of the (S,S,S)-(αMe)Oic stereoisomer has only been disclosed in a patent,13 where no experimental data to sustain the configurational assignment made for the α carbon are given.
Scheme 1.
Reported synthesis for (R,S,S)-(αMe)Oic (ref. 14).
On approaching the preparation of enantiopure (S,S,S)-(αMe)Oic, Seebach’s self reproduction of chirality methodology15 could not be applied because the precursor amino acid (S,S,S)-1 fails to undergo condensation with trichloroacetaldehyde14 to produce the desired oxazolidinone (Scheme 1). The steric hindrance of the cyclohexane group in (S,S,S)-1, on a cis relative orientation with respect to the carboxylic function precludes the formation of oxazolidinone (R,S,S,S)-2. Such a tricyclic system would suffer from severe steric clash14 between nearby hydrogens at the inner concave face. In fact, we proved14 that the aforementioned condensation reaction constitutes a very effective tool for the separation of epimeric mixtures of (R,S,S)-1 and (S,S,S)-1.
Although the steric shielding imposed by the cyclohexane ring in (S,S,S)-1 was truly advantageous for the selective preparation of (R,S,S)-(αMe)Oic,14 it prevents the application of the self-reproduction of chirality strategy15 when the synthesis of the epimeric (S,S,S)-(αMe)Oic is pursued. In that sense, it is rather unfortunate because this powerful methodology would formally allow α-methylation with complete retention of configuration.
We then found that the steric shielding introduced by the cyclohexane moiety could inflict unambiguous facial stereodifferentiation on the enolate derived from (S,S,S)-1. On this basis, it seems reasonable to consider that this spatial effect could effectively govern the stereochemical outcome of direct alkylations performed on a suitably protected derivative of (S,S,S)-1 such as (S,S,S)-3 (Fig. 2).
Figure 2.
Proposed precursor for the synthesis of (S,S,S)-(αMe)Oic.
Compound (S,S,S)-3 was prepared from enantiomerically pure (S,S,S)-1, which, in turn, was obtained in a single step and high yield from commercially available (S)-indoline-2-carboxylic acid as already described.11 Protection of the carboxylic acid and amino functionalities in (S,S,S)-1 was carried out by treatment with methanol in the presence of thionyl chloride and subsequent reaction with di-tert-butyl dicarbonate (Scheme 2).
Scheme 2.
Synthesis of enantiomerically pure (S,S,S)-3. Reagents and conditions: (a) See ref. 11; (b) SOCl2, MeOH, r.t.; (c) Boc2O, iPr2EtN, 4-dimethylaminopyridine, THF, r.t.
Next, we addressed the study of the α-methylation reaction of (S,S,S)-3 through the generation of an intermediate enolate. It appears that the treatment of (S,S,S)-3 with LDA in THF at −78 °C generated a lithium enolate that successfully reacted with methyl iodide in high yield. Thus, a mixture of the two possible diastereoisomers, (S,S,S)-4 and (R,S,S)-4, was isolated in 92% yield, after 12 h of reaction at −60 °C (Scheme 3). In comparison, the use of either LHMDS or KHMDS as a base, led to poor conversions (∼50%) under similar reaction conditions.
Scheme 3.
α-Methylation reaction of (S,S,S)-3. Reagents and conditions: (a) LDA, MeI, THF, −78 to −60 °C; (b) 3N HCl / EtOAc, r.t.
A 89:11 diastereomeric ratio was established by analysis of the relative intensities of appropriate signals in the 1H NMR spectra of the amino ester hydrochlorides (S,S,S)-5 and (R,S,S)-5,16 that were quantitatively obtained after treatment of the crude mixture of (S,S,S)-4/(R,S,S)-4 with a saturated solution of hydrogen chloride in ethyl acetate.
The stereoselectivity attained is rather significant given that the direct α-methylation reaction of equally protected L-proline furnishes racemic (αMe)Pro.17 In the case of N-Boc prolines with additional substituents at the ring, the reported diastereoselectivities are low to moderate, with few exceptions.18 In our case, the high steric hindrance imposed by the cis-fused cyclohexane ring allows an efficient facial stereodifferentiation that translates into a good diastereoselectivity.
The major diastereoisomer of the (S,S,S)-4/(R,S,S)-4 mixture was isolated pure19 in 75% yield after column chromatography (Sheme 4). Subsequent acidic treatment led to the corresponding amino ester hydrochloride, which furnished colourless single crystals suitable for X-ray diffraction analysis.20 The crystalline structure (Fig. 3) showed an (S,S,S) stereochemistry, with a cis relative disposition of the hydrogen atoms at the ring junction and the α-methyl group, thus confirming that the alkylation reaction proceeded with retention of configuration at the quaternary stereocenter.
Figure 3.
X-ray crystal structure of (S,S,S)-5·HCl. Most hydrogens have been omitted for clarity.
Additionally, the basic hydrolysis of (S,S,S)-4 furnished the N-Boc amino acid (S,S,S)-6 in excellent yield (Scheme 4). This Oic derivative is suitably protected for incorporation into peptides.
Scheme 4.
Synthesis of enantiopure (S,S,S)-(αMe)Oic derivatives. Reagents and conditions: (a) LDA, MeI, THF, −78 to −60 °C; column chromatography of the mixture (SiO2, EtOAc/Hexanes 1:10) furnishes pure (S,S,S)-4; (b) 3N HCl / EtOAc, r.t.; (c) 1N KOH, MeOH / H2O, reflux.
In conclusion, this initial study shows that enantiopure (S,S,S)-(αMe)Oic can be accessed by means of a diastereoselective α-methylation reaction on (S,S,S)-3, which is easily derived from (S,S,S)-Oic. The facial stereodifferentiation imposed by the cyclohexane ring on the nucleophilic enolate carbon derived from (S,S,S)-3 accounts for the selective outcome of the α-methylation reaction. Such a spatial effect can thus be regarded as an effective tool for stereocontrol induction during the functionalization at the α carbon for those sterically hindered proline-type substrates where the formation of a trichloromethyloxazolidinone is not possible.
Acknowledgments
Financial support from the Ministerio de Educación y Ciencia–FEDER (project CTQ2007-62245) and Gobierno de Aragón (project PIP206/2005 and research group E40) is gratefully acknowledged. This project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, under contract number N01-CO-12400. The content of this publication does not necessarily reflect the view of the policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organization imply endorsement by the U.S. Government. This research was supported (in part) by the Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research.
References
- 1.Adessi C, Soto C. Curr. Med. Chem. 2002;9:963–978. doi: 10.2174/0929867024606731. [DOI] [PubMed] [Google Scholar]
- 2.(a) Cowell SM, Lee YS, Cain JP, Hruby VJ. Curr. Med. Chem. 2004;11:2785–2798. doi: 10.2174/0929867043364270. [DOI] [PubMed] [Google Scholar]; (b) Toniolo C, Crisma M, Formaggio F, Peggion C. Biopolymers (Pept. Sci.) 2001;60:396–419. doi: 10.1002/1097-0282(2001)60:6<396::AID-BIP10184>3.0.CO;2-7. [DOI] [PubMed] [Google Scholar]; (c) Hruby VJ, Li G, Haskell-Luevano C, Shenderovich M. Biopolymers (Pept. Sci.) 1997;43:219–266. doi: 10.1002/(SICI)1097-0282(1997)43:3<219::AID-BIP3>3.0.CO;2-Y. [DOI] [PubMed] [Google Scholar]
- 3.(a) Calaza MI, Cativiela C. Eur. J. Org. Chem. 2008:3427–3448. doi: 10.1002/ejoc.200800225. [DOI] [PMC free article] [PubMed] [Google Scholar]; (b) Karoyan P, Sagan S, Lequin O, Quancard J, Lavielle S, Chassaing G. In: Substituted Prolines: Syntheses and Applications in Structure-Activity Relationship Studies of Biologically Active Peptides. In Targets in Heterocyclic Systems. Chemistry and Properties. Attanasi OA, Spinelli D, editors. Vol. 8. Cambridge: Royal Society of Chemistry; 2005. pp. 216–273. [Google Scholar]
- 4.(a) Alfakih K, Hall AS. Expert Opin. Pharmacother. 2006;7:63–71. doi: 10.1517/14656566.7.1.63. [DOI] [PubMed] [Google Scholar]; (b) Hurst M, Jarvis B. Drugs. 2001;61:867–896. doi: 10.2165/00003495-200161060-00020. [DOI] [PubMed] [Google Scholar]; (c) Todd PA, Fitton A. Drugs. 1991;42:90–114. doi: 10.2165/00003495-199142010-00006. [DOI] [PubMed] [Google Scholar]
- 5.(a) Reissmann S, Imhof D. Curr. Med. Chem. 2004;11:2823–2844. doi: 10.2174/0929867043364135. [DOI] [PubMed] [Google Scholar]; (b) Stewart JM. Peptides. 2004;25:527–532. doi: 10.1016/j.peptides.2003.10.016. [DOI] [PubMed] [Google Scholar]
- 6.Monteagudo ES, Calvani F, Catrambone F, Fincham CI, Madami A, Meini S, Terracciano R. J. Pept. Sci. 2001;7:270–283. doi: 10.1002/psc.321. [DOI] [PubMed] [Google Scholar]
- 7.Hereafter, a nomenclature without numerical locants at the stereochemical descriptors will be adopted for the sake of simplicity.
- 8.(a) Tang X, Liégault B, Renaud J-L, Bruneau C. Tetrahedron: Asymmetry. 2006;17:2187–2190. [Google Scholar]; (b) Kim YH. Acc. Chem. Res. 2001;34:955–962. doi: 10.1021/ar000187z. [DOI] [PubMed] [Google Scholar]
- 9.(a) Belvisi L, Colombo L, Colombo M, Di Giacomo M, Manzoni L, Vodopivec B, Scolastico C. Tetrahedron. 2001;57:6463–6473. [Google Scholar]; (b) Pyne SG, Javidan A, Skelton BW, White AH. Tetrahedron. 1995;51:5157–5168. [Google Scholar]
- 10.(a) Vincent M, Marchand B, Remond G, Jaguelin-Guinamant S, Damien G, Portevin B, Baumal J-Y, Volland J-P, Bouchet J-P, Lambert P-H, Serkiz B, Luitjen W, Laubie M, Schiavi P. Drug Des. Discovery. 1992;9:11–28. [PubMed] [Google Scholar]; (b) Blankley CJ, Kaltenbronn JS, DeJohn DE, Werner A, Bennett LR, Bobowski G, Krolls U, Johnson DR, Pearlman WM, Hoefle ML, Essenburg AD, Cohen DM, Kaplan HR. J. Med. Chem. 1987;30:992–998. doi: 10.1021/jm00389a006. [DOI] [PubMed] [Google Scholar]; (c) Vincent M, Remond G, Portevin B, Serkiz B, Laubie M. Tetrahedron Lett. 1982;23:1677–1680. [Google Scholar]
- 11.Sayago FJ, Jiménez AI, Cativiela C. Tetrahedron: Asymmetry. 2007;18:2358–2364. doi: 10.1016/j.tetasy.2008.11.030. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.(a) Alatorre-Santamaría S, Rodriguez-Mata M, Gotor-Fernández V, de Mattos MC, Sayago FJ, Jiménez AI, Cativiela C, Gotor V. Tetrahedron: Asymmetry. 2008 doi: 10.1016/j.tetasy.2008.06.010. in press (DOI:10.1016/j.tetasy.2008.06.010). [DOI] [PMC free article] [PubMed] [Google Scholar]; (b) Hirata N. 20050106690 U.S. Patent.
- 13.Barvian NC, Connolly CJC, Guzzo PR, Hamby JM, Hicks JL, Johnson MR, Le V-D, Mitchell LH, Roark WH. 2004092132 PCT Patent WO.
- 14.Sayago FJ, Calaza MI, Jiménez AI, Cativiela C. Tetrahedron. 2008;64:84–91. doi: 10.1016/j.tet.2007.10.095. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15. Seebach D, Boes M, Naef R, Schweizer WB. J. Am. Chem. Soc. 1983;105:5390–5398. Wang H, Germanas JP. Synlett. 1999:33–36. Seebach’s self reproduction of chirality methodology formally allows the direct α-alkylation of L-proline, with complete retention of configuration, through the formation of an intermediate oxazolidinone.
- 16.1H NMR of the crude mixture of the N-Boc protected esters (S,S,S)-4 and (R,S,S)-4 was complex and unsuitable for the determination of the diastereomeric ratio due to the presence of conformational rotamers.
- 17.Clive DLJ, Li Z, Yu M. J. Org. Chem. 2007;72:5608–5617. doi: 10.1021/jo070664s. [DOI] [PubMed] [Google Scholar]
- 18.Williams RM, Cao J. Tetrahedron Lett. 1996;37:5441–5444. [Google Scholar]
- 19.Analytical and spectroscopic data for (S,S,S)-4: Oil. [α]D +9.5 (c 0.95, CHCl3). IR (neat) ν 1743, 1693 cm–1. 1H NMR (DMSO-d6, 400 MHz) δ 1.06 (m, 1H), 1.14–1.50 (m, 3H), overlapped with 1.30, 1.36 (two s, 9H), and with 1.43, 1.45 (two s, 3H), 1.54–1.68 (m, 4H), 1.94–2.10 (m, 1H), 2.11–2.25 (m, 1H), 2.40–2.48 (m, 1H), 3.60–3.72 (m, 1H) overlapped with 3.60, 3.65 (two s, 3H). 13C NMR (DMSO-d6,100 MHz) δ (duplicate signals are observed for most carbons) 20.10, 20.21; 21.77, 23.13; 23.00, 23.23; 25.03, 25.11; 25.65, 26.46; 27.85, 28.01; 33.62, 34.54; 38.87, 39.97; 51.86, 52.04; 57.52, 57.68; 64.40; 78.41, 78.52; 151.66, 152.32; 174.37, 174.66. HRMS (ESI) C16H27NO4Na [M + Na]+: calcd. 320.1832, found 320.1832.
- 20.Crystallographic data for (S,S,S)-5 · HCl: orthorhombic, space group P212121; a = 7.7814(2) Å, b = 8.9278(4) Å, c = 17.6054(7) Å; Z = 4; dcalcd = 1.269 g.cm−3; 8032 reflections collected, 2640 unique (Rint = 0.021); data/parameters: 2640/137; final R indices (I > 2σI): R1 = 0.025, wR2 = 0.060; final R indices (all data): R1 = 0.031, wR2 = 0.061. Highest residual electron density: 0.23 e Å−3. Crystallographic data (excluding structure factors) for this structure have been deposited with the Cambridge Crystallographic Data Centre as supplementary publication number CCDC 694571. Copies of the data can be obtained, free of charge, on application to CCDC, 12 Union Road, Cambridge CB2 1EZ, UK [fax: +44(0)-1223-336033 or e-mail: deposit@ccdc.cam.ac.uk].







